A phase 1 clinical trial of the ELI-002 2P vaccine involving 25 patients with pancreatic and colorectal cancers who had KRAS mutations and minimal residual disease after standard treatment has found evidence suggesting that the off-the-shelf vaccine can produce an immune response against the cancer.
Vaccine Shows Promise Against Pancreatic, Bowel Cancers